Strategies for producing faster acting antidepressants

Drug Discovery Today

Volumn 10, Issue 8, 2005, Pages 578-585

  Adell, Albert ^a   Castro, Elena ^b   Celada, Pau ^a   Bortolozzi, Analía ^a   Pazos, Angel ^b   Artigas, Francesc ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIDEPRESSANT AGENT; APREPITANT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CITALOPRAM; CLOMIPRAMINE; DU 125530; DULOXETINE; FLUOXETINE; HORMONE RELEASE INHIBITING FACTOR; L 759274; MIANSERIN; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NBI 37582; NORASTERRIQUINONE B1; PINDOLOL; PLACEBO; ROBALZOTAN; SB 247464; SB 723620; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE; VN 2222;

ANXIETY DISORDER; BLOOD BRAIN BARRIER; CELL COMMUNICATION; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; ELECTROCONVULSIVE THERAPY; FEEDBACK SYSTEM; GABAERGIC TRANSMISSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEARNING; LIGAND BINDING; LIVER TOXICITY; MEMORY; MONOAMINERGIC SYSTEM; NAUSEA; NERVE CELL PLASTICITY; NONHUMAN; RAPHE NUCLEUS; RECEPTOR DOWN REGULATION; RESPONSE TIME; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; DEPRESSIVE DISORDER; HUMANS; TIME FACTORS;

EID: 17544368021     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03398-2     Document Type: Review

References (86)

1. Caldecott-Hazard S., et al. Clinical and biochemical aspects of depressive disorders: II. Transmitter/Receptor theories. Synapse. 9:1991;251-301
2. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226
3. 1A antagonists. Trends Neurosci. 19:1996;378-383
4. Nestler E.J., et al. Neurobiology of depression. Neuron. 34:2002;13-25
5. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl.). 90:1986;131-138
6. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:1990;289-299
7. Pollock B.G., et al. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch. Gen. Psychiatry. 46:1989;29-35
8. Sheline Y.I., et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 19:1999;5034-5043
9. Drevets W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry. 48:2001;813-829
10. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249
11. Thase M.E., et al. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 178:2001;234-241
12. Adell A., Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol. 343:1991;237-244
13. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15:1993;243-245
14. Artigas F., et al. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22:2001;224-228
15. Artigas F., et al. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251
16. Ballesteros J., Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affect. Disord. 79:2004;137-147
17. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 24:2001;209-229
18. Rabiner D., et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry. 158:2001;2080-2082
19. Invernizzi R.W., Garatiini S. Role of presynaptic α2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28:2004;819-827
20. 1A receptor occupancy in the monkey brain. Neuropsychopharmacology. 22:2000;422-429
21. 11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl) -N-(2-py ridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J. Pharmacol. Exp. Ther. 301:2002;1144-1150
22. Takeuchi K., et al. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1. Bioorg. Med. Chem. Lett. 13:2003;1903-1905
23. Mewshaw R.E., et al. Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. J. Med. Chem. 47:2004;3823-3842
24. Page M.E., et al. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J. Pharmacol. Exp. Ther. 302:2002;1220-1227
25. 1A receptor agonist. Neuropsychopharmacology. 28:2003;445-456
26. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 28:2003;402-412
27. Pazos A., et al. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 21:1987;123-139
28. Pasqualetti M., et al. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience. 92:1999;601-611
29. 2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl.). 167:2003;72-78
30. 2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl.). 133:1997;99-101
31. 18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol. Psychiatry. 45:1999;180-186
32. 2A receptors by agonists and antagonists. Brain Res. Bull. 56:2001;441-451
33. 2A antagonist (M100907) and the SSRI fluoxetine on DRL 72-s behavior. Soc. Neurosci. Abstr. 27:2001;975-978
34. 2C receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology. 29:2004;1782-1789
35. Zhang W., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 23:2000;250-262
36. 7 receptors in guinea-pig brain. Br. J. Pharmacol. 115:1995;107-116
37. 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol. Pharmacol. 47:1995;99-103
38. 7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology. 21:1999;352-367
39. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8547-8551
40. 3H]mesulergine: comparison to other mammalian species. Br. J. Pharmacol. 141:2004;92-104
41. Helke C.J., et al. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J. 4:1990;1606-1615
42. Culman J., et al. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. 280:1997;238-246
43. Sergeyev V., et al. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport. 10:1999;3967-3970
44. 1 receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol. Toxicol. 41:2001;877-906
45. Maeno H., et al. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Mol. Brain Res. 18:1993;43-58
46. 3 binding sites. Neuroscience. 116:2003;761-773
47. Shirayama Y., et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res. 739:1996;70-78
48. Sartori S.B., et al. Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain. Neuropharmacology. 46:2004;1177-1183
49. Kramer M.S., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645
50. 1) receptor antagonist in major depression. Neuropsychopharmacology. 29:2004;385-392
51. Adell A. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Curr. Drug Targets CNS Neurol. Disord. 3:2004;113-121
52. Blier P., et al. Impact of substance P receptor antagonism and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. 29:2004;208-218
53. Haddjeri N., Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol. Psychiatry. 50:2001;191-199
54. Conley R.K., et al. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. 22:2002;7730-7736
55. Santarelli L., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1912-1917
56. 1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 21:2001;8188-8197
57. Guiard B.P., et al. Blockade of substance P (neurokinin 1) receptor enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. 89:2004;54-63
58. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry. 49:2001;391-404
59. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 29:2004;185-193
60. Nemeroff C.B. The corticotrophin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry. 1:1996;336-342
61. A receptor subunits in frontal cortical brain region. J. Neurosci. 24:2004;1478-1483
62. 1 receptor antagonist. Eur. J. Pharmacol. 323:1997;21-26
63. Ducottet C., et al. Effects of the selective nonpeptide corticotrophin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27:2003;625-631
64. Zobel A.W., et al. Effects of the high-affinity corticotrophin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34:2000;171-181
65. Boyer P.A., et al. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 10:1998;219-233
66. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 375:1999;31-40
67. Layer R.T., et al. Antidepressant-like actions of the polyamine site NMDA antagonist eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52:1995;621-627
68. Berman R.M., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 47:2000;351-354
69. O'Neill M., et al. AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3:2004;181-194
70. Calfa C., et al. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocrinology. 28:2003;687-710
71. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501
72. Belanoff J.K., et al. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21:2001;516-521
73. Bremner J.D., et al. Hippocampal volume reduction in major depression. Am. J. Psychiatry. 157:2000;115-118
74. Müller M.B., et al. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur. J. Neurosci. 14:2001;1603-1612
75. Malberg J., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20:2000;9104-9110
76. Thome J., et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20:2000;4030-4036
77. Altar C.A. Neurotrophins and depression. Trends Pharmacol. Sci. 20:1999;59-61
78. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry. 57:2000;925-935
79. Eisch A.J., et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol. Psychiatry. 54:2003;994-1005
80. Pollack S.J., Harper S.J. Small molecule Trk receptor agonists and other neurotrophic factor mimetics. Curr. Drug Targets CNS Neurol. Disord. 1:2002;59-80
81. Fujimaki K., et al. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology. 22:2000;42-51
82. Dailly E., et al. Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. 18:2004;601-607
83. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 12:(Suppl 3):1997;S7-S14
84. Freeman H. Early onset of action of amineptine. Int. Clin. Psychopharmacol. 12:(Suppl 3):1997;S29-S33
85. Zhang W., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 23:2000;250-262
86. Ichikawa J., et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation, a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531